BIOCRYST PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 22.00 thousand shares for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-27.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2017-02-27
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2015-12-31 was 0.00 shares.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2015-09-30 was 0.00 shares.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2015-06-30 was 0.00 shares.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2015-03-31 was 1.00K shares.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2016 was 22.00K shares, a 2100.00% increase from fiscal 2015.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2015 was 1.00K shares.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2013 was 53.00K shares, a 38.37% decline from fiscal 2012.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2012 was 86.00K shares, a 975.00% increase from fiscal 2011.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month |
|---|---|---|---|---|
| 2016-12-31 | 22.00K shares 10-K · filed 2017-02-27 | |||
| 2015-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | 0.00 shares derived: sum of 2 quarters · filed 2017-02-27 | 0.00 shares derived: sum of 3 quarters · filed 2017-02-27 | 1.00K shares 10-K · filed 2017-02-27 |
| 2015-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | 0.00 shares derived: sum of 2 quarters · filed 2015-11-06 | 1.00K shares 10-Q · filed 2015-11-06 | |
| 2015-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | 1.00K shares 10-Q · filed 2015-08-07 | ||
| 2015-03-31 | 1.00K shares 10-Q · filed 2015-05-08 | |||
| 2013-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | 24.00K shares derived: sum of 2 quarters · filed 2016-02-26 | 35.00K shares derived: sum of 3 quarters · filed 2016-02-26 | 53.00K shares 10-K · filed 2016-02-26 |
| 2013-09-30 | 24.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | 35.00K shares derived: sum of 2 quarters · filed 2013-11-08 | 53.00K shares 10-Q · filed 2013-11-08 | 122.00K shares derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-06-30 | 11.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | 29.00K shares 10-Q · filed 2013-08-08 | 98.00K shares derived: sum of 3 quarters · filed 2015-03-02 | 102.00K shares derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-03-31 | 18.00K shares 10-Q · filed 2013-05-09 | 87.00K shares derived: sum of 2 quarters · filed 2015-03-02 | 91.00K shares derived: sum of 3 quarters · filed 2015-03-02 | |
| 2012-12-31 | 69.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | 73.00K shares derived: sum of 2 quarters · filed 2015-03-02 | 86.00K shares 10-K · filed 2015-03-02 | |
| 2012-09-30 | 4.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | 17.00K shares 10-Q · filed 2012-11-08 | ||
| 2012-06-30 | 13.00K shares 10-Q · filed 2012-08-08 | |||
| 2011-12-31 | 8.00K shares 10-K · filed 2014-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |